VERAXA Biotech AG (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, is expanding its use of human-relevant testing methods across its oncology research programs, seeking to generate more clinically informative preclinical data while reducing the number of animals required for drug development. In an October 7, 2026, company announcement, the Switzerland-based biotechnology company, with a key financial and regulatory presence in the U.S., outlined its implementation of New Approach Methodologies (NAMs), a collection of non-animal research techniques that includes cell-based assays, computational modeling and three-dimensional spheroid models.
The strategy supports development of the company’s BiTAC® T-cell engagers, BiTAC-based antibody-drug conjugates and bispecific antibody-drug conjugates for the treatment of cancer. New three-dimensional spheroid data reportedly reinforce the ability of VERAXA’s models to assess the dual-target specificity of its lead T-cell engager candidates. In an ex vivo study involving 10 low-passage patient-derived xenograft models of non-small cell lung cancer, the company required about 10 mice, compared with an estimated 200 or more for comparable in vivo efficacy studies. The company says its lead BiTAC candidate induced potent T-cell-mediated tumor-cell killing across the tested models, while relevant controls showed minimal activity.
The adoption of NAMs matters because it may improve the translational relevance of preclinical findings to human biology, potentially increasing the probability of success in clinical trials while reducing reliance on animal testing—a growing priority for regulators and investors. For readers, this could signal a more efficient path to new cancer treatments and a shift in how biotechnology companies validate drug candidates. For the industry, VERAXA’s move aligns with FDA efforts to modernize drug development through human-relevant testing approaches.
VERAXA Biotech (NASDAQ: VRXA) is implementing these methods across its preclinical research programs, aiming to streamline development of its antibody-based cancer pipeline. The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA.
MissionIR, a specialized communications platform, distributes syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution and a full array of tailored corporate communications solutions.
Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer.
